LobbyingMolecular Testing Labs lobbying by quarter
Molecular Testing Labs's latest lobbying report covers Q1 2025, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Molecular Testing Labs
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $30K | 1 |
| Q1 2023 | $30K | 2 |
| Q2 2023 | $50K | 2 |
| Q3 2023 | $30K | 2 |
| Q4 2023 | $30K | 2 |
| Q1 2024 | $30K | 2 |
| Q2 2024 | $30K | 2 |
| Q3 2024 | $30K | 2 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$260K · 9 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES9 reports
- SENATE9 reports
Firms it paid
| Firm | ||
|---|---|---|
| Ascendant Strategic Partners | $240K | 8 quarters |
| ML Strategies | $20K | 8 quarters |
| Hart Health Strategies | $0 | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ALEXANDER NATHAN HECHT | Chief Counsel, Senate Committee on Small Business & Entrepreneurship | Q2 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 25/04/21for Q1 2025 | ML Strategies | Under $5,000 |
| 25/01/21for Q4 2024 | ML Strategies | Under $5,000 |
| 24/10/21for Q3 2024 | ML Strategies | Under $5,000 |
| 24/10/15for Q3 2024 | Ascendant Strategic Partners | $30K |
| 24/07/19for Q2 2024 | ML Strategies | Under $5,000 |
| 24/07/03for Q2 2024 | Ascendant Strategic Partners | $30K |
| 24/05/02for Q1 2024 | Ascendant Strategic Partners | $30K |
| 24/04/22for Q1 2024 | ML Strategies | Under $5,000 |
| 24/01/19for Q4 2023 | ML Strategies | Under $5,000 |
| 24/01/03for Q4 2023 | Ascendant Strategic Partners | $30K |
| 23/10/20for Q3 2023 | ML Strategies | Under $5,000 |
| 23/10/06for Q3 2023 | Ascendant Strategic Partners | $30K |
| 23/08/01for Q2 2023 | Ascendant Strategic Partners | $30K |
| 23/07/20for Q2 2023 | ML Strategies | $20K |
| 23/05/30for Q1 2023 | Hart Health Strategies | Under $5,000 |
| 23/04/24for Q2 2023 | ML Strategies | Under $5,000 |
| 23/04/13for Q4 2022 | Hart Health Strategies | Under $5,000 |
| 23/04/10for Q1 2023 | Ascendant Strategic Partners | $30K |
| 23/01/03for Q4 2022 | Ascendant Strategic Partners | $30K |